1. Chen W, Zheng R, Baade PD, et al. (2016) Cancer statistics in China, 2015. CA Cancer J Clin, 66(2): 115-32. [DOI:10.3322/caac.21338]

2. Smyth EC, Nilsson M, Grabsch HI, et al. (2020) Gastric cancer. Lancet, 396(10251): 635-648. [DOI:10.1016/S0140-6736(20)31288-5]

3. Patel TH and Cecchini M (2020) Targeted therapies in advanced gastric cancer. Curr Treat Options Oncol, 21(9): 70. [DOI:10.1007/s11940-020-0616-8]

4. Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin, 70(1): 7-30. [DOI:10.3322/caac.21590]

5. Poorolajal J, Moradi L, Mohammadi Y, et al. (2020) Risk factors for stomach cancer: a systematic review and meta-analysis. Epidemiol Health, 42: e2020004. [DOI:10.4178/epih.e2020004]

6. Bravo Neto GP, dos Santos EG, Victer FC, Carvalho CE (2014) Lymph node metastasis in early gastric cancer. Rev Col Bras Cir, 41(1): 11-7. [DOI:10.1590/S0100-69912014000100004]

7. Kodera Y (2013) Gastric cancer with minimal peritoneal metastasis: is this a sign to give up or to treat more aggressively? Nagoya J Med Sci, 75(1-2): 3-10.

8. Riihimäki M, Hemminki A, Sundquist K, et al. (2016) Metastatic spread in patients with gastric cancer. Oncotarget, 7(32): 52307-52316. [DOI:10.18632/oncotarget.10740]

9. Eble JA and Niland S (2019) The extracellular matrix in tumor progression and metastasis. Clin Exp Metastasis, 36(3): 171-198. [DOI:10.1007/s10585-019-09966-1]

10. Paolillo, M and Schinelli S (2019) Extracellular Matrix Alterations in Metastatic Processes. Int J Mol Sci, 20(19). [DOI:10.3390/ijms20194947]

11. Jabłońska-Trypuć, A, Matejczyk M, Rosochacki S (2016) Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J Enzyme Inhib Med Chem, 31(sup1): 177-183. [DOI:10.3109/14756366.2016.1161620]

12. Läubli H and Borsig L (2019) Altered cell adhesion and glycosylation promote cancer immune suppression and metastasis. Front Immunol, 10: 2120. [DOI:10.3389/fimmu.2019.02120]

13. Doyle AD, Nazari SS, Yamada KM (2022) Cell-extracellular matrix dynamics. Phys Biol, 19(2). [DOI:10.1088/1478-3975/ac4390]

14. Linder S, Cervero P, Eddy R, Condeelis J (2023) Mechanisms and roles of podosomes and invadopodia. Nat Rev Mol Cell Biol, 24(2): 86-106. [DOI:10.1038/s41580-022-00530-6]

15. Mao L, Whitehead CA, Paradiso L, et al. (2018) Enhancement of invadopodia activity in glioma cells by sublethal doses of irradiation and temozolomide. J Neurosurg, 129(3): 598-610. [DOI:10.3171/2017.5.JNS17845]

16. Saha T and Gil-Henn H (2021) Invadopodia, a Kingdom of Non-Receptor Tyrosine Kinases. Cells, 10(8). [DOI:10.3390/cells10082037]

17. Saykali BA and El-Sibai M (2014) Invadopodia, regulation, and assembly in cancer cell invasion. Cell Commun Adhes, 21(4): 207-12. [DOI:10.3109/15419061.2014.923845]

18. Wu B, Wang YX, Wang JJ, et al. (2022) PLXDC2 enhances invadopodium formation to promote invasion and metastasis of gastric cancer cells via interacting with PTP1B. Clin Exp Metastasis, 39(4): 691-710. [DOI:10.1007/s10585-022-10168-5]

19. Sun J, He H, Pillai S, et al. (2013) GATA3 transcription factor abrogates Smad4 transcription factor-mediated fascin overexpression, invadopodium formation, and breast cancer cell invasion. J Biol Chem, 288(52): 36971-82. [DOI:10.1074/jbc.M113.506535]

20. Schnoor M, Stradal TE, Rottner K (2018) Cortactin: Cell Functions of A Multifaceted Actin-Binding Protein. Trends Cell Biol, 28(2): 79-98. [DOI:10.1016/j.tcb.2017.10.009]

21. Daly RJ (2004) Cortactin signalling and dynamic actin networks. Biochem J, 382(Pt 1): 13-25. [DOI:10.1042/BJ20040737]

22. Kirkbride KC, Sung BH, Sinha S, Weaver AM (2011) Cortactin: a multifunctional regulator of cellular invasiveness. Cell Adh Migr, 5(2): 187-98. [DOI:10.4161/cam.5.2.14773]

23. Helgeson LA and Nolen BJ (2013) Mechanism of synergistic activation of Arp2/3 complex by cortactin and N-WASP. Elife, 2: e00884. [DOI:10.7554/eLife.00884]

24. Jeannot P and Besson A (2020) Cortactin function in invadopodia. Small GTPases, 11(4): 256-270. [DOI:10.1080/21541248.2017.1405773]

25. Weaver AM(2008) Cortactin in tumor invasiveness. Cancer Lett, 265(2): 157-66. [DOI:10.1016/j.canlet.2008.02.066]

26. Wang L, Zhao K, Ren B, et al. (2015) Expression of cortactin in human gliomas and its effect on migration and invasion of glioma cells. Oncol Rep, 34(4): 1815-24. [DOI:10.3892/or.2015.4156]

27. Zhang X, Liu K, Zhang T, et al. (2017) Cortactin promotes colorectal cancer cell proliferation by activating the EGFR-MAPK pathway. Oncotarget, 8(1): 1541-1554. [DOI:10.18632/oncotarget.13652]

28. Wei J, Wang Y, Xie B, et al. (2022) Cortactin and HER2 as potential markers for dural-targeted therapy in advanced gastric cancer. Clin Exp Med, 22(3): 403-410. [DOI:10.1007/s10238-021-00752-6]

29. Wei J, Zhao ZX, Li Y, et al. (2014) Cortactin expression confers a more malignant phenotype to gastric cancer SGC-7901 cells. World J Gastroenterol, 20(12): 3287-300. [DOI:10.3748/wjg.v20.i12.3287]

30. Cui N, Hu M, Khalil RA (2017) Biochemical and biological attributes of matrix metalloproteinases. Prog Mol Biol Transl Sci, 147: 1-73. [DOI:10.1016/bs.pmbts.2017.02.005]

31. Humphries MJ (2009) Cell adhesion assays. Methods Mol Biol, 522: 203-10. [DOI:10.1007/978-1-59745-413-1_14]

32. Xie D, Liu L, Osaiweran H, et al. (2015) Detection and Characterization of Metastatic Cancer Cells in the Mesogastrium of Gastric Cancer Patients. PLoS One, 10(11): e0142970. [DOI:10.1371/journal.pone.0142970]

33. Kanner SB, Reynolds AB, Vines RR, Parsons JT (1990) Monoclonal antibodies to individual tyrosine-phosphorylated protein substrates of oncogene-encoded tyrosine kinases. Proc Natl Acad Sci USA, 87(9): 3328-32. [DOI:10.1073/pnas.87.9.3328]

34. Gunst SJ (2004) Actions by actin: reciprocal regulation of cortactin activity by tyrosine kinases and F-actin. Biochem J, 380(Pt 2): e7-8. [DOI:10.1042/bj20040559]

35. Wu H, Cheng X, Ji X, et al. (2016) Cortactin contributes to the tumorigenicity of colorectal cancer by promoting cell proliferation. Oncol Rep, 36(6): 3497-3503. [DOI:10.3892/or.2016.5207]

36. Sheen-Chen SM, Huang CY, Liu YY, et al. (2011) Cortactin in breast cancer: analysis with tissue microarray. Anticancer Res, 31(1): 293-7.

37. Huang X, Ji J, Xue H, et al. (2012) Fascin and cortactin expression is correlated with a poor prognosis in hepatocellular carcinoma. Eur J Gastroenterol Hepatol, 24(6): 633-9. [DOI:10.1097/MEG.0b013e3283515a18]

38. Chuma M, Sakamoto M, Yasuda J, et al. (2004) Overexpression of cortactin is involved in motility and metastasis of hepatocellular carcinoma. J Hepatol, 41(4): 629-36. [DOI:10.1016/j.jhep.2004.06.018]

39. Nakane K, Fujita Y, Terazawa R, et al. (2012) Inhibition of cortactin and SIRT1 expression attenuates migration and invasion of prostate cancer DU145 cells. Int J Urol, 19(1): 71-9. [DOI:10.1111/j.1442-2042.2011.02888.x]

40. Di Martino JS, Akhter T, Bravo-Cordero JJ (2021) Remodeling the ECM: Implications for Metastasis and Tumor Dormancy. Cancers (Basel), 13(19). [DOI:10.3390/cancers13194916]

41. Winkler J, Abisoye-Ogunniyan A, Metcalf KJ, Werb Z (2020) Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun, 11(1): 5120. [DOI:10.1038/s41467-020-18794-x]

42. Perrin L and Gligorijevic B (2022) Proteolytic and mechanical remodeling of the extracellular matrix by invadopodia in cancer. Phys Biol, 20(1). [DOI:10.1088/1478-3975/aca0d8]

43. Eddy RJ, Weidmann MD, Sharma VP, Condeelis JS (2017) Tumor Cell Invadopodia: Invasive Protrusions that Orchestrate Metastasis. Trends Cell Biol, 27(8): 595-607. [DOI:10.1016/j.tcb.2017.03.003]

44. Liu Y, Lu L, Wen D, et al. (2020) MiR-612 regulates invadopodia of hepatocellular carcinoma by HADHA-mediated lipid reprogramming. J Hematol Oncol, 13(1): 12. [DOI:10.1186/s13045-019-0841-3]

45. Karamanou K, Franchi M, Vynios D, Brézillon S (2020) Epithelial-to-mesenchymal transition and invadopodia markers in breast cancer: Lumican a key regulator. Semin Cancer Biol, 62: 125-133. [DOI:10.1016/j.semcancer.2019.08.003]

46. Sun J, Lu F, He H, et al. (2014) STIM1- and Orai1-mediated Ca(2+) oscillation orchestrates invadopodium formation and melanoma invasion. J Cell Biol, 207(4): 535-48. [DOI:10.1083/jcb.201407082]

47. Yamaguchi H, Pixley F, Condeelis J (2006) Invadopodia and podosomes in tumor invasion. Eur J Cell Biol, 85(3-4): 213-8. [DOI:10.1016/j.ejcb.2005.10.004]

48. Xue Y, Li M, Hu J, et al. (2022) Ca(v)2.2-NFAT2-USP43 axis promotes invadopodia formation and breast cancer metastasis through cortactin stabilization. Cell Death Dis, 13(9): 812. [DOI:10.1038/s41419-022-05174-0]

49. Li Y, Zhang H, Gong H, et al. (2018) miR-182 suppresses invadopodia formation and metastasis in non-small cell lung cancer by targeting cortactin gene. J Exp Clin Cancer Res, 37(1): 141. [DOI:10.1186/s13046-018-0824-1]

50. Niland S, Riscanevo AX, Eble JA (2021) Matrix Metalloproteinases Shape the Tumor Microenvironment in Cancer Progression. Int J Mol Sci, 23(1). [DOI:10.3390/ijms23010146]

51. Jacob A, Jing J, Lee J, et al. (2013) Rab40b regulates trafficking of MMP2 and MMP9 during invadopodia formation and invasion of breast cancer cells. J Cell Sci, 126(Pt 20): 4647-58. [DOI:10.1242/jcs.126573]

52. Jiang H and Li H (2021) Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis. BMC Cancer, 21(1): 149. [DOI:10.1186/s12885-021-07860-2]

53. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol, 18(5): 1135-49. [DOI:10.1200/JCO.2000.18.5.1135]

54. Clark ES, Whigham AS, Yarbrough WG, Weaver AM (2007) Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Cancer Res, 67(9): 4227-35. [DOI:10.1158/0008-5472.CAN-06-3928]